Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Clinical and Translational Oncology

• Publication date

  2020-09-30

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1007/s12094-020-02490-9PMID 32997278
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

  2020cited by this paper
• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

  2020cited by this paper
• Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

  2019cited by this paper
• Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma.

  2019cited by this paper
• Amendment history : Expression of Concern ( July 2019 ) Tandem CAR T cells targeting HER 2 and IL 13 R a 2 mitigate tumor antigen escape

  2019cited by this paper
• Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

  2019cited by this paper
• Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

  2019cited by this paper
• Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.

  2019cited by this paper
• Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates

  2019influential reference
• DNA-scaffolded biomaterials enable modular and tunable control of cell-based cancer immunotherapies

  2019cited by this paper
• CAR-T cell therapy: a potential new strategy against prostate cancer

  2019cited by this paper
• Solid Tumors Challenges and New Insights of CAR T Cell Engineering

  2019cited by this paper
• Chimeric antigen T cell receptor treatment in hematological malignancies

  2019influential reference
• Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

  2019cited by this paper
• TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells

  2018cited by this paper
• Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

  2018cited by this paper
• Engineering Axl specific CAR and SynNotch receptor for cancer therapy

  2018cited by this paper
• Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors

  2018cited by this paper
• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

  2018influential reference
• Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

  2018cited by this paper
• Universal CARs, universal T cells, and universal CAR T cells

  2018cited by this paper
• Making CAR T Cells a Solid Option for Solid Tumors

  2018cited by this paper
• Engineering CAR-T Cells for Improved Function Against Solid Tumors

  2018cited by this paper
• Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell

  2018cited by this paper
• Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy

  2018cited by this paper
• Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells

  2018cited by this paper
• Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

  2017cited by this paper
• Use of Alternative Medicine for Cancer and Its Impact on Survival.

  2017cited by this paper
• A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

  2017cited by this paper
• Immunooncology: Can the Right Chimeric Antigen Receptors T-Cell Design Be Made to Cure All Types of Cancers and Will It Be Covered?

  2017cited by this paper
• Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9

  2017cited by this paper
• CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

  2017cited by this paper
• Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells

  2017cited by this paper
• A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

  2017cited by this paper
• CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors.

  2017cited by this paper
• Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis

  2017cited by this paper
• Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody

  2017cited by this paper
• Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

  2017cited by this paper
• mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting

  2017cited by this paper
• Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

  2017cited by this paper
• Design of chimeric antigen receptors with integrated controllable transient functions

  2016cited by this paper
• Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

  2016cited by this paper
• Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.

  2016cited by this paper
• Toxicity and management in CAR T-cell therapy

  2016cited by this paper
• Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.

  2016cited by this paper
• Clinical manufacturing of CAR T cells: foundation of a promising therapy

  2016cited by this paper
• Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

  2016cited by this paper
• Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer.

  2016cited by this paper
• Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

  2016cited by this paper
• Versatile strategy for controlling the specificity and activity of engineered T cells

  2016cited by this paper
• Novel Immunotherapies for Hematological Malignancies.

  2016cited by this paper
• Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.

  2016cited by this paper
• T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells.

  2016cited by this paper
• Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

  2016cited by this paper
• T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

  2016cited by this paper
• Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch.

  2015cited by this paper
• Remote control of therapeutic T cells through a small molecule–gated chimeric receptor

  2015cited by this paper
• Redirection of genetically engineered CAR-T cells using bifunctional small molecules.

  2015cited by this paper
• Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy

  2015cited by this paper
• Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

  2014cited by this paper
• Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

  2014cited by this paper
• Simultaneous targeting of prostate stem cell antigen and prostate‐specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell‐retargeting system

  2014cited by this paper
• Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects

  2014cited by this paper
• Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

  2014cited by this paper
• Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

  2014cited by this paper
• A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

  2014cited by this paper
• Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells

  2013cited by this paper
• Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

  2013cited by this paper
• T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

  2013cited by this paper
• Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

  2013cited by this paper
• Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

  2013cited by this paper
• PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

  2013cited by this paper
• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  2013cited by this paper
• TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

  2013cited by this paper
• Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition

  2013cited by this paper
• Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.

  2012cited by this paper
• Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

  2012cited by this paper
• Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

  2012cited by this paper
• A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

  2012cited by this paper
• A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

  2012cited by this paper
• Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

  2012cited by this paper
• An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo

  2012cited by this paper
• Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection

  2012cited by this paper
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

  2011cited by this paper
• T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.

  2011cited by this paper
• Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

  2010cited by this paper
• The canonical Notch signaling pathway: unfolding the activation mechanism.

  2009cited by this paper
• Structural basis for autoinhibition of Notch

  2007cited by this paper
• Notch signalling: a simple pathway becomes complex

  2006cited by this paper
• The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

  2005cited by this paper
• Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.

  2005cited by this paper
• Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells

  2004cited by this paper
• Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration.

  2003cited by this paper
• Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors

  2002cited by this paper
• Ligand-mediated cytolysis of tumor cells: Use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes

  2000cited by this paper
• Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

  1989cited by this paper
• [Technology of processing meat of varying quality].

  1985cited by this paper
• Participation of both 'enkephalinase' and aminopeptidase activities in the metabolism of endogenous enkephalins.

  1983cited by this paper
• Effects of heavy ions on rabbit tissues: analysis of low levels of DNA damage in retinal photoreceptor cells.

  1983cited by this paper
• [Dynamics of the ribonucleoprotein level of the tigroid and mitochondria in the cat's spinal motor neurons during their stimulation and inhibition].

  1973cited by this paper

• Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer

  2025cites this paper
• Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy

  2025cites this paper
• Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical blood cord NK cells for targeting CD19⁺ primary B-ALL cells.

  2025cites this paper
• Integrating CAR-T cells with other immunotherapies for improved efficacy in cancer patients.

  2025cites this paper
• Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy

  2025cites this paper
• CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation.

  2025cites this paper
• Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer’s Disease

  2025cites this paper
• Reprogramming Immunity: Emerging Therapeutic Frontiers and Clinical Trial Advances of CAR-T Cell Therapy in Autoimmune Diseases

  2025cites this paper
• CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions

  2025cites this paper
• The challenges and progress of CAR-T cell therapy in the treatment of solid tumors

  2025cites this paper
• Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy

  2025cites this paper
• CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights

  2025cites this paper
• Epigenetic and post-translational modifications in ferroptosis regulation and hepatocellular carcinoma: New frontiers in therapeutic targeting.

  2025cites this paper
• CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges

  2025cites this paper
• Avances en inmunoterapia para leucemia linfocítica aguda: integración de terapias con células car-T y otras estrategias inmunológicas

  2025cites this paper
• Harnessing IL-27: challenges and potential in cancer immunotherapy

  2025cites this paper
• Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies

  2025cites this paper
• CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy

  2024cites this paper
• Challenges and strategies associated with CAR-T cell therapy in blood malignancies

  2024cites this paper
• The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs.

  2024cites this paper
• CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies

  2024cites this paper
• The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review

  2024cites this paper
• Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

  2024cites this paper
• CAR-NK cell therapy in AML: Current treatment, challenges, and advantage.

  2024cites this paper
• Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer.

  2024cites this paper
• Significant Advancements and Evolutions in Chimeric Antigen Receptor Design

  2024cites this paper
• Current evidence and future direction on evaluating the anticancer effects of curcumin, gingerols, and shogaols in cervical cancer: A systematic review

  2024cites this paper
• Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review.

  2023cites this paper
• Chimeric Antigen Receptor (CAR)-Based Cell Therapy for Type 1 Diabetes Mellitus (T1DM); Current Progress and Future Approaches

  2023cites this paper
• Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.

  2023cites this paper
• CRISPR, CAR-T, and NK: Current applications and future perspectives

  2023cites this paper
• Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future

  2023cites this paper
• Immunogenicity of COVID‐19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta‐analysis

  2023cites this paper
• CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy

  2023cites this paper
• CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies

  2023cites this paper
• Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

  2023cites this paper
• Could CAR-T cell therapy be promising agent in acute lymphoblastic leukemia?

  2022influential citation
• Preclinical acute toxicity studies of the CAR technology products for malignant neoplasms therapy on the example of the «anti-HER2-CAR-T/CAR-NK»

  2022cites this paper
• Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors

  2022cites this paper
• CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer

  2022cites this paper
• CAR-T cell combination therapy: the next revolution in cancer treatment

  2022cites this paper
• Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma

  2022cites this paper
• Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological malignancies.

  2022cites this paper
• Functional Comparison between Endogenous and Synthetic Notch Systems

  2022cites this paper
• An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

  2022cites this paper
• Personalized Immunology in Cancer: Paving the Way Towards a Better Quality of Life

  2021cites this paper
• Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2

  2021cites this paper
• Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies

  2021cites this paper
• Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects

  2021cites this paper
• Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism

  2021cites this paper
• Recent advances in antibody‐based immunotherapy strategies for COVID‐19

  2021cites this paper
• E3 ubiquitin ligase Casitas B lineage lymphoma‐b and its potential therapeutic implications for immunotherapy

  2020cites this paper
• Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients

  2020cites this paper